Clinical Trial Update: Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy [Phase 1, Phase 2]

View source ↗

Summary

The document reports the completion of a Phase 1/2 clinical trial of NP002 in Parkinson's disease. It investigates NP002 as a treatment for Levodopa-induced dys…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• NP002

Snippet

Sponsor: Neuraltus Pharmaceuticals, Inc. | Conditions: Parkinson's Disease | Phase 1, Phase 2 | Status: COMPLETED